Metabolism and excretion of mood stabilizers and new anticonvulsants.
about
Issues in the treatment of epilepsy.Pharmacokinetic considerations in prescribing antiepileptic drugs.Women and bipolar disorder across the life spanA review of postpartum psychosis.Lamotrigine for bipolar disorder: translating research into clinical practice.Clinical use of carbamazepine for bipolar disorders.Safety and tolerability of mood-stabilising anticonvulsants in the elderly.Practical considerations for carbamazepine use in bipolar disorder.The increasing frequency of mania and bipolar disorder: causes and potential negative impacts.Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence.Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach.Reproductive function and risk for PCOS in women treated for bipolar disorder.Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: an open-label study.Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder.Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment.
P2860
Q34091794-C6539A8E-A690-45E0-AE15-B09CF491B005Q34374256-877BC0CB-0754-48E9-9775-27023707C2DEQ35022930-BDBD3509-3C3F-4D56-82DE-4E09F366AF11Q35029281-49ABE962-602D-4F32-A99C-309162F7A3BEQ36106947-A066C4AB-4C0E-461E-ABE6-9BB7D961F515Q36327118-5761429F-20FD-4B0D-BD0F-6B287D5F68D6Q36446899-DCCA20DC-E5AC-4F29-A317-0EA3404CA83CQ36506812-90E224DD-DCBF-4BE7-825B-2E815A94BDEAQ36784587-B81F4E6C-3330-4026-A6B2-8CA72E44B463Q37830040-31EFCD82-E241-4C3C-B653-308CE53F48B1Q40612167-981EDE24-82C9-4B7B-B70B-9CA044134DF8Q44882854-B134FAF7-253F-4119-8E83-92009058FE77Q46494852-66C5DF7E-2D1C-4883-97C9-AA1DE257BFBDQ46495739-EF9A2377-F998-4932-B587-9C6A35D7BCBCQ46861992-CC4F16CC-96C2-45FA-B1A8-50B497E1B41CQ47950809-792C6FA6-185F-4854-A179-CA3B6964BF1D
P2860
Metabolism and excretion of mood stabilizers and new anticonvulsants.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Metabolism and excretion of mood stabilizers and new anticonvulsants.
@ast
Metabolism and excretion of mood stabilizers and new anticonvulsants.
@en
type
label
Metabolism and excretion of mood stabilizers and new anticonvulsants.
@ast
Metabolism and excretion of mood stabilizers and new anticonvulsants.
@en
prefLabel
Metabolism and excretion of mood stabilizers and new anticonvulsants.
@ast
Metabolism and excretion of mood stabilizers and new anticonvulsants.
@en
P2093
P356
P1476
Metabolism and excretion of mood stabilizers and new anticonvulsants.
@en
P2093
Corá-Locatelli G
Kimbrell TA
P2888
P304
P356
10.1023/A:1006990925122
P577
1999-08-01T00:00:00Z
P6179
1025396736